MasterCard has delayed its $2.5bn (€2.1bn) flotation, the largest in the US pipeline, after the credit card company's chief executive underwent surgery for prostate cancer.
The deal was due in the first quarter with Goldman Sachs as the lead underwriter and Citigroup, HSBC and JP Morgan as joint bookrunners.